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Summary
Cholera and malaria are major diseases causing high mortality. The only licensed
cholera vaccine is expensive; immunity is lost in children within 3 years and adults
are not fully protected. No vaccine is yet available for malaria. Therefore, in this
study, the cholera toxin-B subunit (CTB) of Vibrio cholerae fused to malarial vaccine
antigens apical membrane antigen-1 (AMA1) and merozoite surface protein-1
(MSP1) was expressed in lettuce and tobacco chloroplasts. Southern blot analysis
confirmed homoplasmy and stable integration of transgenes. CTB-AMA1 and CTB-
MSP1 fusion proteins accumulated up to 13.17% and 10.11% (total soluble protein,
TSP) in tobacco and up to 7.3% and 6.1% (TSP) in lettuce, respectively. Nine groups
of mice (n = 10 ⁄group) were immunized subcutaneously (SQV) or orally (ORV) with
purified antigens or transplastomic tobacco leaves. Significant levels of antigen-spe-
cific antibody titres of immunized mice completely inhibited proliferation of the
malarial parasite and cross-reacted with the native parasite proteins in immunoblots
and immunofluorescence studies. Protection against cholera toxin challenge in both
ORV (100%) and SQV (89%) mice correlated with CTB-specific titres of intestinal,
serum IgA and IgG1 in ORV and only IgG1 in SQV mice, but no other immunoglobu-
lin. Increasing numbers of interleukin-10+ T cell but not Foxp3+ regulatory T cells,
suppression of interferon-c and absence of interleukin-17 were observed in pro-
tected mice, suggesting that immunity is conferred via the Tr1 ⁄ Th2 immune
response. Dual immunity against two major infectious diseases provided by chloro-
plast-derived vaccine antigens for long-term (>300 days, 50% of mouse life span)
offers a realistic platform for low cost vaccines and insight into mucosal and systemic
immunity.
Introduction
Cholera is one among the top three diseases listed by the
World Health Organization and the mortality rate is esti-
mated to be 100, 000–150, 000 deaths annually (Longini
et al., 2007). Rapidly waning immunity with infection both
from human and environmental sources has been recently
reported (King et al., 2008). However, only one interna-
tionally licensed cholera vaccine is available but this
remains prohibitively expensive for routine use in cholera-
endemic areas in developing countries (Mahalanabis et al.,
2008), especially at times of outbreak. Also, with the cur-
rent cholera vaccine, immunity is lost in children within
3 years and adults are not fully protected (Olsson and Par-
ment, 2006) suggesting the need for durable and low
cost cholera vaccine. Vibrio cholerae secretes a 86-kDa
toxin that is made up of two subunits: an a- and a b-sub-
unit (CTB) that contains binding site for the plasma
membrane receptor of the intestinal epithelial cells (GM1;
de Haan et al., 1998; Tsuji et al., 1995) and this is an
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ideal antigen candidate for oral vaccine (Tacket
et al.,1998, 2004).
Malaria is also a devastating global health problem in
tropical and subtropical areas of over 100 countries. Plas-
modium falciparum is the most virulent species with
approximately 500 million cases, 1 million deaths annually
and more than 2 billion people are at risk for malaria
(Greenwood et al., 2005; Langhorne et al., 2008). There
are many challenges in developing a vaccine against
malaria because of the complexity of antigens, high poly-
morphism among parasitic proteins, lack of appropriate
animal models, high cost of vaccine development and
delivery (Aide et al., 2007). Currently, there is no licensed
vaccine for prevention of malaria. Current clinical trials are
under way investigating several blood-stage candidates
such as apical membrane antigen-1 (AMA1), merozoite
surface protein-1 (MSP1) and erythrocyte surface antigen
(Greenwood et al., 2005; Maher, 2008).
Mucosal- and gut-associated lymphatic tissues represent
unique architecture of the immune system (Mora and von
Andrian, 2008) and provide a major site of entry for many
gastrointestinal, respiratory and urogenital infections, caus-
ing severe acute diseases (Holmgren and Czerkinsky,
2005; Rescigno and Chieppa, 2005). This compartment of
the immune system constitutes a first line of defense by
providing antigen-specific local IgA, systemic antigen-spe-
cific immunoglobulins and generation of cytotoxic T cells.
Advantages of oral plant-based vaccines have been
described previously (Daniell et al., 2005; Holmgren and
Czerkinsky, 2005; Davoodi-Semiromi et al., 2009).
The skyrocketing expense of current vaccines can be
attributed to their unnecessarily complex production and
delivery methods—from the significant cost of fermenta-
tion systems to purification through the use of complex
technologies and additional expenses associated with adju-
vant, cold storage, transportation and sterile delivery. This
unconventional concept uses freeze-dried plant cells for
bio-encapsulation of vaccine antigens that are protected in
the stomach from acids and enzymes but are released to
the immune system in the gut when plant cell walls are
digested by bacteria that colonize the gut (Limaye et al.,
2006; Arlen et al., 2008). Several vaccine antigens have
been produced in nuclear transgenic plants for oral deliv-
ery against bacterial pathogens (Brodzik et al., 2009) and
shown to elicit immunoglobulin response and protection
upon oral delivery in humans (Tacket et al., 1998, 2004)
and in mice (Arakawa et al., 1998; Nochi et al., 2007).
Also, plant-derived recombinant F1, V and F1-V fusion
antigens of Yersinia pestis protected guinea pigs against
an aerosol challenge of virulent Y. pestis (Del Prete et al.,
2009). One of the major limitations has been the ability to
accumulate sufficient levels of protein, either for purifica-
tion or for oral delivery in minimally processed plant tis-
sues. The integration of transgenes via the nuclear
genome may have other disadvantages including trans-
gene containment, gene silencing and position effect.
Moreover, no transgenic plant-based vaccine has moved
beyond phase I clinical trial (Yusibov and Rabindran,
2008), highlighting the need to explore new technologies.
The chloroplast genetic engineering approach can
address concerns on transgene containment (Daniell,
2002). Genetically modified chloroplast genomes of most
crops are maternally inherited and the absence of any
reproductive structures offer efficient foreign gene con-
tainment and facilitate their safe production in the field
(Daniell, 2007). It also overcomes the concerns of gene
silencing and position effect (De Cosa et al., 2001; Lee
et al., 2003) and pleiotropic effects (Lee et al., 2003; Ruiz
et al., 2003). Multigene engineering is possible with chlo-
roplast transformation because of its prokaryotic nature
(Grevich and Daniell, 2005; Quesada-Vargas et al., 2005).
In addition, chloroplasts are highly efficient bioreactors
(Daniell et al., 2002, 2004; Daniell, 2006; Verma et al.,
2008; Davoodi-Semiromi et al., 2009) and it is possible to
produce up to 360 million doses of fully functional anthrax
vaccine in one acre of tobacco (Koya et al., 2005). Several
therapeutic proteins and vaccine antigens have been
expressed via the chloroplast genome against bacterial,
viral and protozoan pathogens, including the CTB (Daniell
et al., 2001), heat labile toxin-B subunit (Rosales-Mendoza
et al., 2009), anthrax protective antigen (Watson et al.,
2004; Koya et al., 2005), plague F1-V (Arlen et al., 2008),
tetanus toxin (Tregoning et al., 2003, 2005), vaccinia virus
(Rigano et al., 2009), the 2L21 peptide from the canine
parvovirus (Molina et al., 2004, 2005), HEV E2 of Hepatitis
E virus (Zhou et al., 2006) and the GAL ⁄GALNAc lectin of
Entamoeba histolytica (Chebolu and Daniell, 2007). These
vaccine antigens expressed in transgenic chloroplasts have
proper post-translational modifications and are fully func-
tional by appropriate immune response in animal models
and ⁄or protection conferred against pathogen or toxin
challenge. Oral delivery of plant cells producing human
proinsulin in chloroplasts prevented the onset of type 1
diabetes in non-obese diabetic mice (Ruhlman et al., 2007).
Oral immunization (ORV) of chloroplast-derived F1-V anti-
gens without adjuvant conferred greater protection (88%)
against 50-fold lethal dose of aerosolized plague (Yersinia
pestis) than subcutaneous (SQV) immunization (33%)
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(Arlen et al., 2008). Optimal protection against diseases
upon oral delivery of vaccine antigens demonstrate that
chloroplast can produce fully functional antigens, survive in
the stomach by bioencapsulation and when released in the
gut, make vaccine more efficacious than the same protein
delivered through the perenteral route.
However, one among the major limitations in this field
is the expression of several therapeutic proteins in tobacco,
which is not suitable for oral delivery. To avoid prohibi-
tively expensive purification, cold storage ⁄ transportation
and achieve oral delivery, optimal expression of therapeutic
proteins in chloroplasts of edible crops is necessary. We
developed the carrot plastid transformation system with
adequate levels of gene expression in the edible parts to
facilitate oral delivery (Kumar et al., 2004); however, the
regeneration is extremely slow and it is not suitable for
rapid production of therapeutic proteins. Although high
level expression of human immunodeficiency virus p24
antigen was observed in tomato leaves, there was a >90%
reduction in green fruits and no expression was observed
in red ripe fruits (Zhou et al., 2008). The lettuce chloro-
plast transformation has been developed by several groups
(Lelivelt et al., 2005; Kanamoto et al., 2006) but expres-
sion of therapeutic proteins was unsuccessful. We have
optimized the lettuce plastid transformation system and in
this study attempt to express vaccine antigens. The level of
expression in lettuce chloroplast is similar to tobacco and
regeneration is as rapid as tobacco, the most successful
plastid transformation system developed so far.
In this study, we conjugated CTB with two major malarial
vaccine antigens, AMA1 and MSP1, in tobacco and lettuce
chloroplasts and female BALB ⁄ c mice were immunized
orally with tobacco transplastomic leaves or subcutaneously
with purified or enriched vaccine antigens. Different groups
of immunized mice and control were challenged with chol-
era toxin and sera were evaluated against the malarial para-
site. Oral immunization provided both mucosal and
systemic immunity while subcutaneously immunized mice
developed systemic immunity. Increasing numbers of inter-
leukin (IL)-10+CD4+ T cell along with higher concentration
of antigen-specific IgG1 suggests that Tr1 ⁄ Th2 type immu-
nity was generated in immunized mice. Numbers of Foxp3+
regulatory T cells, IL-17 and interferon (IFN)-c do not play
any significant role in protection against cholera toxin chal-
lenge. Sera of mice immunized with the malarial vaccine
antigens markedly blocked proliferation of the malarial par-
asite in red blood cells (RBC), confirming efficacy and speci-
ficity of generated antibody against the malarial parasite.
This study provides insight into the longevity of mucosal
and systemic immunity and confirms that durable immunity
can be maintained in older mice with additional boosters.
High level of protection conferred by chloroplast-derived
CTB conjugated with the malarial vaccine antigens should
facilitate development of a low cost multivalent vaccine for
large populations, at times of outbreak.
Results
Characterization of lettuce and tobacco
transplastomic lines expressing vaccine antigens
Tobacco chloroplast vectors contained the trnI (Ile) and trnA
(Ala) genes while lettuce chloroplast vectors contained
16S ⁄ trnI and trnA ⁄23S genes as flanking sequences (longer
flanking sequence than tobacco) for homologous recombi-
nation with the native chloroplast genome (Ruhlman et al.,
2007). Expression cassettes for vaccine antigens CTB-
AMA1 and CTB-MSP1 were regulated by endogenous psbA
promoter, 5¢-untranslated region (UTR) to enhance transla-
tion and the 3¢-UTR to confer transcript stability (Figure 1).
CTB-AMA1 fusion included the GPGP (Gly Pro Gly Pro)
hinge region and the furin cleavage site while CTB-MSP1
included only the GPGP hinge in between fusion proteins
to facilitate correct folding of each protein by reducing the
steric hindrance. The native plastid ribosomal operon
promoter (Prrn) was used to drive expression of the aadA
gene from the GGAG ribosome binding site for spectino-
mycin resistance. After completion of chloroplast vectors
pLD CTB-AMA1, pLD CTB-MSP1, pLsDV CTB-AMA1 and
pLsDV CTB-MSP1 (Figure 1), plasmids were isolated,
sequenced and used for chloroplast transformation studies.
Transplastomic tobacco and lettuce plants were obtained
as described previously (Kanamoto et al., 2006; Ruhlman
et al., 2007; Verma et al., 2008). Five to six primary tobacco
and 3–6 lettuce transformants (per 10 bombardments)
appeared 3–6 weeks after bombardment from leaves placed
on the regeneration medium containing the selection agent.
Duration of lettuce regeneration and efficiency of transfor-
mation is very similar to tobacco. Primary transformants
were screened by polymerase chain reaction (PCR) using
3P ⁄3M and 5P ⁄2M primer pairs in tobacco and 16SF ⁄3M
and 5P ⁄2M primer pairs in lettuce (data not shown). Follow-
ing an additional round of selective regeneration, progeni-
tors for each transplastomic line was rooted in medium
containing the selection agent. Clones were transferred to
Jiffy (Jiffy Products (N.B.) Ltd, Shippagan, Canada) peat
pots, acclimatized in biodome and moved to the green-
house, where they matured, flowered and produced seeds.
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Southern blot analysis confirmed site specific transgene
integration into the chloroplast genome and homoplasmy
in all tobacco and lettuce transgenic lines (Figure 2).
Tobacco CTB-AMA1 and CTB-MSP1 transplastomic lines
yielded 6.6- and 6.5-kb fragment respectively while
untransformed line yielded a 4.1-kb fragment (Figure 2a).
Lettuce transplastomic lines with CTB-AMA1 yielded
11.6 kb and CTB-MSP1 yielded 11.5 kb, while untrans-
formed lines yielded 9.1-kb fragment (Figure 2b). The
absence of untransformed fragment in lettuce and
tobacco transplastomic lines confirmed that they achieved
homoplasmy. Presence of the CTB-coding sequence in
transplastomes was confirmed by the CTB probe
(Figure 2c).
Expression, quantitation and enrichment of vaccine
antigens
Immunoblots were performed with tobacco and lettuce
transplastomic lines expressing CTB-AMA1 and CTB-MSP1
(Figures 3a–d). Immunodetection with CTB polyclonal anti-
body showed 11.5 kDa of the CTB monomer, 27.5 kDa
monomer of CTB fused with AMA1 and a 23 kDa mono-
mer of CTB fused with MSP1 (Figures 3a–d). The forma-
tion of dimers, trimers, tetramers and pentamers of CTB-
AMA1 and CTB-MSP1 fusion proteins was observed in
tobacco as well as in lettuce. Foreign proteins could be
detected in the supernatant and pellet (Figures 3a,b).
Therefore, the quantitation of CTB-AMA1 and CTB-MSP1
was performed using homogenate.
The CTB-AMA1 expression level of tobacco T0 and T1
transplastomic lines in mature leaves reached up to
13.17% and 12.41% of the TSP respectively. The CTB-
MSP1 expression level of tobacco T0 and T1 transplastom-
ic lines in mature leaves reached up to 10.11% and 9.9%
of the TSP respectively. In lettuce T0 and T1, CTB-AMA1
expression level reached up to 7.3% and 7.26% of the
TSP, respectively in mature leaves under the green-house
growth conditions. In lettuce T0 and T1, CTB-MSP1
expression level reached up to 6.1% and 5.89% of the
TSP, respectively in mature leaves under the green-house
growth conditions. A gram of mature leaf contained up to
3.56 mg or 1.21 mg of CTB-AMA1 fusion protein in
tobacco or lettuce respectively. A gram of mature leaf
contained up to 2.72 or 0.83 mg of CTB-MSP1 antigen in
transformed tobacco or lettuce respectively.
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Figure 1 Schematic representation of the lettuce and tobacco chloroplast constructs. Schematic representation of the lettuce and tobacco
chloroplast genome-flanking sequences used for homologous recombination, probe DNA sequence and chloroplast transformation vectors
including the transgene cassettes for cholera toxin-B subunit (CTB)-apical membrane antigen-1, CTB-merozoite surface protein-1, integration sites
and anticipated products of the transplastomic lines in Southern blots. represents lettuce 16s ribosomal operon promoter; represents lettuce
3¢ rbcL; represents lettuce psbA promoter including 5¢-untranslated region (UTR); represents lettuce psbA 3¢UTR; represents tobacco psbA
promoter including 5¢UTR; represents tobacco psbA 3¢UTR; represents tobacco 16s ribosomal operon promoter.
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To determine the affinity of plant-derived CTB fusion
protein for the GM1-ganglioside receptor, GM1-enzyme-
linked-immunosorbent assay (ELISA) was performed.
GM1-ganglioside has been shown to be the receptor for
CTB protein in vivo (de Haan et al., 1998) and a penta-
meric structure is required for binding to GM1 receptor
(Tsuji et al., 1995). To address whether CTB fusion protein
generated in transplastomic tobacco and lettuce retained
biological activities and could bind to the GM1 receptor,
we performed GM1-binding ELISA assay. As illustrated in
Figure 3e, transplastomic CTB-AMA1 and CTB-MSP1 pro-
teins are fully functional and bind to GM1. These results
suggest that the tobacco and lettuce chloroplast-derived
CTB-AMA1 and CTB-MSP1 assemble properly to form
pentameric structures, which are essential for GM1-gangli-
oside receptor binding.
Cholera toxin was shown to bind to immobilized Ni2+
ion mediated by the B subunit and is a useful affinity purifi-
cation method for CTB and complexes composed of CTB
(Dertzbaugh and Cox, 1998). Therefore, for enrichment
crude plant extract was subjected to immobilized metal
affinity chromatography using the TALON Superflow Metal
Affinity Resin (Clontech, Mountain View, CA, USA) and
run on NuPAGE Novex Bis–Tris gradient gel under reducing
and non-reducing conditions. The large subunit of Rubisco
(55 kDa) was present in the untransformed, lysate and
flow through fractions under reduced and non-reduced
conditions (Figure 4a). In the wash fractions, minimal num-
ber of proteins were observed. In the eluted CTB-AMA1
fraction, the monomer of 27.5 kDa in size was present
under reduced conditions (lane 6) and the pentameric form
was present under both reduced (lane 6) and non-reduced
(lane 12) conditions (Figure 4a). It should be noted that the
pentameric form was the dominant form and this should
facilitate GM1 binding. An immunoblot probed with anti-
CTB antibody was conducted to evaluate the CTB-malarial
proteins after talon enrichment. An immunoblot with
known concentrations of CTB protein and different con-
centrations of the enriched fractions was probed with anti-
CTB antibody. Quantitation of the enriched CTB-malarial
proteins on immunoblots was analysed by densitometry.
Linearity of the standard curve assisted in the estimation of
the enriched samples in the same blot (Figure 4b,c). The
efficiency of the talon enrichment was determined to be
90% and 73% in CTB-AMA1 and CTB-MSP1, respectively.
Tobacco transplastomic lines were available before let-
tuce and therefore animal studies were performed with
tobacco. Because presence of nicotine or other alkaloids
has been a disadvantage for human oral delivery studies,
it is important to create lettuce lines. Lettuce leaves are
consumed without cooking by humans and the time from
sowing seed to obtain biomass is only few weeks when
compared with few months for other crops (such as
tomato, potato and carrot). Therefore, lettuce lines
expressing CTB-AMA1 and CTB-MSP1 were developed.
Humoral immunity in vaccinated mice confers
protection against cholera toxin challenge
The immunization schedule is shown in Figure 5a. Con-
trol and immunized BALB ⁄ c mice were challenged with
9.1 kb
11.6 kb 11.5 kb
6.6 kb
3
6.5 kb
4.1 kb
1 2 3 4 5 6 7
1 2
1 2  3 4
11.5 kb11.6 kb
(a)
(c)
(b)
Figure 2 Southern blots analyses of transgenic plants. Genomic DNA
(2 lg) was digested with HindIII in lettuce and ApaI in tobacco
untransformed and transplastomic lines. The blots were hybridized
with the lettuce or tobacco-flanking sequence or cholera toxin-B
subunit (CTB) probes. (a) Tobacco; lane 1: untransformed (4.1 kb),
lane 2: homoplasmic CTB-merozoite surface protein-1 (MSP1; 6.5 kb)
and lane 3: homoplasmic CTB-apical membrane antigen-1 (AMA1)
(6.6 kb) lines. (b) Lettuce; lane 1: untransformed (9.1 kb), lane 2:
blank, lanes 3 and 4: homoplasmic CTB-AMA1 (11.6 kb) lines, lane 5:
untransformed, lanes 6 and 7: homoplasmic CTB-MSP1 (11.5 kb)
lines. (c) Lettuce probed with CTB. Lanes 1–3: transplastomic lines,
lane 4: untransformed.
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cholera toxin for 14 h. Then mice were euthanized and
intestinal content was collected. A significant (P < 0.0001)
correlation was observed between volume of intestinal
water retention in SQV and ORV mice and protection
(Figure 5b). There was no significant difference between
these two groups (Figure 5b). All of control mice (100%),
adjuvant (AJV) and ⁄or immunized mice with untransformed
leaf materials were not protected (Figure 5b,c). To explore
impact of CT challenge on immunized ⁄ control mice, we
screened presence ⁄ absence of antigen-specific antibody in
the sera. Antigen-specific ELISA data showed the presence
of antigen-specific CTB-IgA in sera and intestinal content of
ORV-CTB mice but not in any other group of mice tested,
suggesting a direct correlation between IgA production and
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Figure 3 Expression of vaccine antigens in transgenic chloroplasts. Tobacco (2 lg) or lettuce (3 lg) of TSP were separated on SDS-PAGE, trans-
ferred on nitrocellulose membrane and hybridized with the cholera toxin-B subunit (CTB) primary antibody. (a) CTB-apical membrane antigen-1
(AMA1) in tobacco and lettuce. Lane 1: standard CTB (100 ng), lane 2: untransformed extract, lanes 3 and 4: Tobacco CTB-AMA1 supernatant
and pellet, lanes 5 and 6: Lettuce CTB-AMA1 supernatant and pellet. (b) CTB-merozoite surface protein-1 (MSP1) in tobacco and lettuce. Lane 1:
CTB standard (100 ng), lane: 2 untransformed extract, lanes 3 and 4: tobacco CTB-MSP1 supernatant and pellet, lanes 5 and 6: lettuce CTB-MSP1
supernatant and pellet. (c) CTB-AMA1 in tobacco and lettuce with known quantities of the CTB standard. Lanes 1–3: CTB standard (50, 100 and
200 ng), lane 4: untransformed extract, lanes 5 and 6: tobacco CTB-AMA1 T0 and T1 transplastomic lines, lanes 7 and 8: lettuce CTB-AMA1 T0
and T1 transplastomic lines. (d) CTB-MSP1 in tobacco and lettuce with known quantities of CTB standard. Lanes 1–3: CTB standard (50, 100 and
200 ng), lane 4: untransformed extract, lanes 5 and 6: tobacco CTB-MSP1 T0 and T1 transplastomic lines, lanes 7 and 8: lettuce CTB-MSP1 T0
and T1 transplastomic lines. Monomers, dimers and pentamers are shown with arrows. (e) CTB-GM1 binding assay of CTB-AMA1 and CTB-MSP1
tobacco and lettuce T0 and T1 transplastomic lines. Lanes 1 and 2: tobacco CTB-AMA1 T0 and T1, lanes 3 and 4: lettuce CTB-AMA1 T0 and T1,
lanes 5 and 6: tobacco CTB-MSP1 T0 and T1, lanes 7 and 8: lettuce CTB-MSP1 T0 and T1 transplastomic lines, lane 9: untransformed plant, lane
10: phosphate-buffered saline.
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oral immunization (Figure 5c). It should be noted that IgA
titres repeatedly and reproducibly observed in ORV-CTB
mice in this study were much higher than those reported in
previous studies (Arlen et al., 2008).
In contrast, in SQV mice that were protected from CT
challenge, we were unable to detect any CTB-IgA in sera
and ⁄or in intestinal content by ELISA. To investigate the
mechanism of protection observed in SQV mice, we
screened a broad range of antigen-specific immunoglobu-
lins by ELISA including -IgG1, -IgG2a, -IgG2b, -IgG3 and
-IgM using sera of vaccinated and control mice. As shown
in Figure 6a, our data show that only CTB-IgG1 but not
any other tested immunoglobulin conferred protection in
SQV mice (Figure 6a, top row). Screening of the same
profile of immunoglobulins in the sera of ORV mice
showed comparable pattern of expression with SQV
mice (Figure 6a) suggesting superiority of oral vaccination
because orally immunized mice not only generated
systemic antibodies like the other groups but in addition
generated mucosal immunity, while the other groups
failed to do so. These data suggest that immune responses
to the same antigen might be different and this is depen-
dent on the route of immunization. Furthermore, we
screened additional antigen-specific antibodies including
CTB-IgG1, -IgG2a, -IgG2b, -IgG3 and -IgM in the sera
of vaccinated mice before (bleed # 5) and after CT
challenge. Our data suggest that only antigen-specific
CTB-IgM antibody level significantly changed after CT
challenge but not any other antibodies tested (Figure 6a,
bottom row).
To understand whether CT challenge might modulate
the immune responses towards the Th1 (T-helper-1), Th2
(T-helper-2) and ⁄or Th17 in immunized ⁄ control mice, we
further screened expression of IL-4 (Th2), IL-10 (Th2), IL-2
(Th1), IFNc (Th1) and IL-17A (Th17) by ELISA in the sera.
Our data show that expression of IFNc was detected in
70% (seven of 10 mice), 16.6% (one of six mouse) and
10% (one of 10 mice) of control, SQV and ORV-CTB mice,
respectively suggesting that immunization blocks Th1
immune response. However, IL-17A is unlikely to play a
role in this system because only 11% in SQV (one in nine)
and 10% (one in 10 mice) in ORV-CTB groups were posi-
tive for IL-17 when examined by ELISA.
Kinetics of antigen-specific IgA in sera obtained from
orally immunized mice showed an increase in antibody
titre associated with the number of boosters. This data
also showed that about five oral boosts are required to
generate high levels of immunity (Figure 6b). There was
significant variation in immune titres within the same
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Figure 4 Enrichment of chloroplast-derived cholera toxin-B subunit
(CTB) malarial antigens. (a) CTB FC apical membrane antigen-1
(AMA1) protein was extracted from transformed leaves and the crude
extract was subjected to Talon Superflow Metal Affinity Resin and
analysed. Molecular size standards are indicated in lanes 1 and 7.
Lanes 2–6: reduced and lanes 8–12: non-reduced conditions of CTB
FC AMA1 protein enrichment was observed by using a gradient gel
(4%–12%) and gel electrophoresis. The following proteins are visual-
ized: lanes 2 and 8: untransformed, lanes 3 and 9: lysate, lanes 4 and
10: flow through, lanes 5 and 11: wash, and lanes 6 and 12: enriched
protein. (b) Immunoblot analysis of tobacco CTB FC AMA1 using CTB
primary antibody, lanes 1–4: CTB standard (1000, 500, 250 and
125 ng respectively), lane 5: protein marker, lanes 6–9: eluted CTB FC
AMA1 (1.5, 0.75, 0.375 and 0.1875 lg respectively). (c) Immunoblot
analysis of tobacco CTB-merozoite surface protein-1 (MSP1) using CTB
primary antibody. Lanes 1–4: CTB standard (1000, 500, 250 and
125 ng respectively), lanes 5–7: eluted CTB MSP1 (1.5, 0.75 and
0.375 lg respectively). Eluted proteins and CTB were subjected to
densitometry to determine the enrichment of CTB FC AMA1 and
CTB-MSP1 to be administered to mice for subcutaneous injection.
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group, even though BALB ⁄ c is an inbred strain. However,
all animals were protected after toxin challenge in this
group, showing that high levels of immune titres are
probably not required for protection against the pathogen.
Based on this data, to prolong immunity, additional boost-
ers may be desirable but not required.
Protected mice had higher expression of interleukin-
10+CD4+ T cells but not Foxp3+CD4+ T cells
Further investigations were performed to understand cellu-
lar immunity. Expression of different markers associated
with T cells and antigen-presenting dendritic cells (DC) in
freshly prepared splenocytes obtained from controls
(unvaccinated) and vaccinated mice after CT challenge was
measured. As shown in Figure 7a, CT challenge eliminated
CD4+IL10+ T cells in unvaccinated control mice after CT
challenge but CD4+IL10+ T cells markedly ameliorated in
this population in SQV and ORV-CTB mice, suggesting that
IL-10 expressing CD4 T cells (Tr1 regulatory T cells) may
play a protective role in adaptive immunity generated by
immunization. However, CT challenge did not increase
numbers of CD4+CD25+ T cells population in control mice
after CT challenge but moderately increased this popula-
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Figure 5 The experimental design and evaluation of cholera toxin (CT) challenge on control and immunized mice. (a) The immunization sche-
dule is shown by a horizontal line. Arrows from left to right show initial priming on day 0. Mice received twelve oral boosters (small vertical
arrows) and six subcutaneous boosters (short bars with solid circles). Mice were bled five-times (grey-filled cylinder) and terminal bleeding
(hatched cylinder) was performed 14 h post-challenge. Days of oral and s.c boosts are shown below and on the top of the horizontal arrow
respectively. Days of bleeding are shown on top of each cylinder. (b) CT challenge in control and vaccinated mice. CT (1.5 lg ⁄ g of body
weight) was challenged orally for 14 h. Each spot represents intestinal water content (lL) of an individual mouse in different groups after
CT challenge (one-way ANOVA, P < 0.0001). (c) CTB-antigen-specific serum and intestinal IgA in different groups of mice measured by antigen-
specific enzyme-linked-immunosorbent serologic assay. Control (Ctrl), adjuvant (ADJ), subcutaneous vaccinated (SQV) and orally vaccinated
(ORV) mice.
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tion on SQV and ORV mice when compared with control
mice. Intriguingly, CT challenge dramatically ameliorated
numbers of CD4+Foxp3+ regulatory T cell in unvaccinated
mice after CT challenge (2.5-fold) and this effect was
moderate in SQV (ranged from 7.2% to 12.5%) and in
ORV-CTB mice (range from 11.5% to 14%) (Figure 7b,
middle row). In contrast, as shown in Figure 7b, CT
decreased expression of IL7Ra (CD127) in unvaccinated
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Figure 6 Mechanisms of generated immunity in vaccinated and control mice. (a) Sera of SQV and ORV-cholera toxin-B subunit (CTB) mice were
evaluated for antigen-specific immunoglobulins using CTB-specific enzyme-linked-immunosorbent serologic assay as shown in each panel. Top row
shows CTB-IgG1 and -IgG2a titres; middle row shows CTB-IgG2b and IgG3 titres; the bottom row shows serum CTB-IgM titres before and after
CT challenge in oral and subcutaneously immunized mice. Data represent one of at least 3–5 independent experiments for any given immunoglob-
ulin. Ctrl, control; SQV, subcutaneous immunization; ORV, oral immunization. (b) Determination of effectiveness of numbers of boosters to gener-
ate CTB-specific serum IgA in orally gavaged mice with transplastomic leaves. Ten-week-old mice were boosted subcutaneously (until 189 days) or
orally (until 219 days). Sera were collected until 197 days post-immunization.
ª 2009 The Authors
Journal compilation ª 2010 Blackwell Publishing Ltd, Plant Biotechnology Journal, 8, 223–242
Dual vaccine for cholera and malaria 231
mice after CT challenge but had marked up-regulation in
SQV and ORV-CTB mice (5%–8%). Based on these data,
vaccinated mice with chloroplast-derived antigen gener-
ated a Tr1 cellular immune response and a Th2 humoral
immune response that correlated with protection against
the toxin challenge.
(a)
(b)
(c)
Figure 7 Single-cell analyses of pooled splenocytes from vaccinated and control mice. (a, b) Flow cytometry analyses were performed on fresh sin-
gle-cell suspension of pooled splenocytes obtained from unimmunized ⁄ control, unimmunized ⁄ cholera toxin (CT) challenged, subcutaneous SQV
and orally ORV-CTB immunized mice after CT challenge as described in Experimental procedures. Shown in rows 1–4 is gated splenocytes CD4+ T
cells population and cells were stained with anti-CD4 antibody followed by staining with anti-interleukin-10 (IL10), CD25, Foxp3 and CD127 anti-
bodies respectively. Intracellular staining of Foxp3 and IL-10 was performed using Foxp3 intracellular staining kit (eBioscience) according to instruc-
tions provided by manufacturer. Shown in row 5 is gated CD4+ T cells population. (c) Post-challenge analysis. Pooled splenocytes of different
groups as depicted were stained with cell surface markers and staining was performed using anti-mouse CD11c-FITC, CD80-PE and biotin-conju-
gated MHC II and then stained with streptavidin-conjugated PerCP (BD Bioscience). Shown is gated splenocytes CD11C+ population (bottom row)
and cells were further stained with anti-CD80 antibody. Purified rat anti-mouse CD16 ⁄CD32 was used for 10 min to block Fc receptor before initi-
ation of cell surface staining. Shown are gated on CD11c+high splenic dendritic cells.
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Impact of cholera toxin challenge on dendritic cells
maturation in immunized mice
We further investigated the role of DC in cellular immunity
generated in immunized mice. We evaluated expression of
major histocompatibility complex (MHC) II, CD40 and
CD80 on CD11c+ DC population, prepared from fresh
splenocytes of 2–5 pooled mice. As shown in Figure 7c,
expression of MHC II and co-stimulatory molecules in
CD11c+ DC in SQV and ORV mice was almost similar to
control unchallenged mice. However, expression of these
markers in control (challenged) mice increased to about
8%–11% when compared with control (unchallenged)
and ORV ⁄ SQV mice. Steady-state expression of CD11c
and co-stimulatory molecule CD80 in immunized mice was
very similar to the phenotype observed in tolerogenic DC.
CT challenge had no or very little effect on maturation of
splenic DC in vaccinated mice. However, CT increased
expression of these markers in the control ⁄ challenged
mice suggesting that immunization minimized the effect
of CT on maturation of DC but not in control mice
challenged with CT.
Antibodies generated in immunized mice cross-
reacted with the Plasmodium antigens
Our data show increasing numbers of boosters with the
malarial vaccine antigens increased the anti-MSP1 anti-
body titres in immunized mice (Figure 8a). Generation of
anti-MSP1 antibody (IgG1) in SQV was higher than ORV
(Figure 8a). As we showed earlier for CTB, ORV mice gen-
erated both systemic and mucosal immune responses for
malarial antigens. However, SQV mice failed to generate
IgA and this may account for lower anti-MSP1 IgG1 anti-
body titres in ORV mice. Limited quantity of AMA1 anti-
gen provided by NIH was a major hurdle in this study.
Therefore, we measured anti-AMA1 antibody in sera of
immunized mice only in few experiments. To assess speci-
ficity of anti-plasmodium antibody in sera of mice immu-
nized with the malarial vaccine antigens, we performed a
series of immunoblots and immunofluorescence studies.
Immunoblot data showed that anti-AMA1 antibody in the
sera (bleed 4) of immunized mice hybridized and recog-
nized schizont protein of Plasmodium as a 83-kDa poly-
peptide (Figure 8b, lane 3). The sera from immunized
mice contained anti-MSP1 antibodies, also bound and rec-
ognized both ring and schizont proteins of Plasmodium as
a 190-kDa polypeptide in the immunoblot (Figure 8b, lane
4). Furthermore, anti-AMA1 antibodies obtained from sera
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Figure 8 Cross-reactivity of antisera generated against transplastomic
malarial vaccine antigens. (a) Detection of anti-merozoite surface pro-
tein-1 (MSP1)19 IgG1 antibody in sera of mice immunized by subcuta-
neous (SQV) and oral (ORV)-MSP1 delivery. Sera of SQV and ORV-MSP1
mice were subjected to an antigen-specific MSP1-IgG1 enzyme-linked-
immunosorbent serologic assay. (b) Immunoblot analysis: 36.8 lg of
cell-free parasite extracts from ring, trophozoite and schizont stages
were resolved on sodium dodecylsulphate polyacrylamide gel electro-
phoresis gels and were subjected to immunoblot analysis using diluted
sera from immunized mice. Sera collected from immunized mice (bleed
4 and was diluted 1 : 5) recognized the native 83-kDa apical membrane
antigen-1 (AMA1) protein (lanes 1–3) and the native 190 kDa MSP-1
protein (lanes 4–6). The parasite stages analysed from Plasmodium falci-
parum 3D7 culture were ring: lanes 1 and 4, trophozoite: lanes 2 and 5
and schizont: lanes 3 and 6. (c) Immunofluorescence analysis: P. falcipa-
rum 3D7 parasites were immunostained with anti-AMA1 (top row) and
anti-MSP1 antibodies (lower row) from immunized mice. Panels 1 and
4 are differential interference contrast images, panels 2 and 5 are fluo-
rescence images, and panel 3 and 6 are merged images of previous
two panels. The AMA1 antibodies recognized the apical end of the par-
asite in the ring developmental stage of intraerythrocytic growth (1, 2
and 3). The MSP-1 sera from immunized mice (bottom row) detected
the developing merozoites at the schizont stage of the parasitic growth
(4, 5 and 6). Bar size = 10 lm.
ª 2009 The Authors
Journal compilation ª 2010 Blackwell Publishing Ltd, Plant Biotechnology Journal, 8, 223–242
Dual vaccine for cholera and malaria 233
of immunized mice successfully hybridized with the apical
end of the parasite at the ring stage as shown in
Figure 8c, further confirming specificity of antibody gener-
ated in immunized mice with chloroplast-derived vaccine
antigen. As shown in Figure 8c, fluorescence-labelled sera
from immunized mice with the chloroplast-derived CTB-
MSP1 antigen successfully stained schizont stage of malar-
ial parasite, further confirming specificity of antibody gen-
erated in vaccinated mice.
Antibodies generated in immunized mice blocks
Plasmodium entry into red blood cells
To examine functionality of antibody generated in immu-
nized mice against Plasmodium, parasite inhibition assays
evaluated the ability of anti-MSP1 antibodies in inhibiting
parasite entry into erythrocytes. We found that the ring
stage was the predominant stage of the parasite under
microscopic examination. Average parasitemia was deter-
mined to be in the range of 5.7%–6.6% in the blank con-
trol samples (no serum added), in untreated control
animals and those gavaged with WT (untransformed)
plants (Table 1). The lowest parasitemia was found to be
associated with MSP-119 group (group 5, s.c MSP1) that
had the highest mean antibody titre (Figure 8a). Erythro-
cytes were protected 100% from parasite entry when they
were treated with serum from positive control (MRA-35
rabbit antiserum purified from recombinant yeast,
PfMSP1–19, 3D7) and successful inhibition was observed
when sera of immunized mice were used to block parasite
entry into erythrocytes. However, sera of control mice
failed to prevent parasite entry (Table 1). In this study, rel-
ative inhibition rate regardless of the route of immuniza-
tion was 86%–117% (±15.5%). Relative inhibition of
Plasmodium with the sera obtained from vaccinated mice
(bleed # 4) was as efficient as or better than the positive
serum used in this study (Table 1). Both oral and injectable
vaccination with AMA-1 conferred 102% or 105% inhibi-
tion in parasitemia assays. Inhibition was slightly less when
both antigens were delivered orally or by injection because
50% less antigen dose was delivered when compared
with single antigens.
Discussion
Currently, there is no licensed vaccine for the prevention
of malarial disease despite the vast knowledge of genom-
ics and proteomics of the malarial parasite (Sharma and
Pathak, 2008). Recently, phase 2a trial of Falciparum
malaria vaccines RTS,S ⁄AS01B and RTS,S ⁄AS02A in
malaria-naive adults has been conducted (Kester et al.,
2009). The only available cholera vaccine is unaffordable
to most people in developing countries as it is highly
expensive (Kim et al., 2008). The high cost of current vac-
cines is mainly because of the method of production using
expensive fermentation, purification and delivery systems.
To address this, several vaccine antigens have been
expressed via the nuclear genome (Yusibov and Rabindran,
2008), which elicited immunogenic response, and con-
ferred protection upon oral delivery (Arntzen, 2008). How-
ever, immunogenic response was often less than adequate
because of insufficient levels of the antigens expressed via
the nuclear genome (Streatfield et al., 2001; Streatfield,
2007). This led to development of an alternate method
using plant chloroplast as bioreactors to produce high lev-
els of vaccine antigens facilitated by >10 000 copies of
transgene in each single transformed plant cells (Daniell
et al., 2001, 2009).
This study is the first report of a vaccine antigen expres-
sion in an ideal oral delivery system in chloroplasts. Expres-
sion of the influenza virus haemagglutinin gene in lettuce
chloroplasts could not be detected in both young and
Table 1 Parasitemia assays and relative inhibition of parasite in
red blood cells (RBC) using sera of immunized and control mice
Group
Parasitemia
(%)
Mean
parasitemia (%)
Relative
inhibition (%)
No Ab 6.6–6.7 6.6 –
MRA-35 PfMSP1–19 2.5–3.5 3.1 100.0
Group 1 (oral WT) 5.9–6.6 6.1 14.3
Group 2 (s.c. adjuvant) 5.5–6.2 5.8 22.8
Group 3 (s.c. AMA1) 2.8–3 2.9 105.8
Group 4 (oral AMA1) 2.4–3.3 3.0 102.8
Group 5 (s.c. MSP1) 2.4–2.6 2.5 117.2
Group 6 (oral MSP1) 2.6–3.6 3.2 97.2
Group 7 (s.c. AMA1
and MSP1)
2.7–3.9 3.3 94.3
Group 8 (oral AMA1
and MSP1)
3.3–3.8 3.6 85.8
Group 9 (untouched) 5.6–5.8 5.7 25.7
Average parasitemia and relative inhibition was determined as shown. The
stage of parasite used was trophozoite-schizont and the haematocrit and
parasitemia were adjusted to 2%. Control and experimental mouse sera
were heat inactivated and incubated with uninfected RBC overnight at
4 C. The mouse serum was added to the parasite culture at a final
concentration of 20%. The cultures were incubated for 48 h to allow for
schizont rupture and merozoite invasion. Assays were preformed in
duplicate and repeated at least three times. Parasitemia was determined
and the relative per cent of inhibition was calculated by using the formula
described in Experimental procedures.
AMA1, apical membrane antigen-1; merozoite surface protein-1.
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mature leaves by immunoblots (Lelivelt et al., 2005). Also
in this study, we report the first chloroplast-derived dual
vaccines by multigene engineering for two major infec-
tious diseases, cholera and malaria. The two of the leading
asexual blood-stage malarial vaccine candidate genes,
AMA1 and MSP1, were cloned along with the transmuco-
sal carrier, CTB, and were successfully expressed via the
tobacco and lettuce chloroplast genomes. We used native
psbA 5¢-UTR regulatory elements in tobacco and lettuce to
drive CTB-AMA1 and CTB-MSP1 as it was shown to
enhance translation of more foreign protein than the
genes regulated by bacteriophage T7 gene 10 translational
elements (Dhingra et al., 2004). The expression levels in
mature leaves of CTB-AMA1 and CTB-MSP1 protein
reached up to 13.17% and 10.11% of TSP respectively in
tobacco, whereas in lettuce, expression levels of CTB-
AMA1 and CTB MSP1 was 7.3% and 6.1% of TSP respec-
tively. The expression levels of CTB-AMA1 in tobacco is
comparable to 14.8% accumulation of F1-V (Arlen et al.,
2008), 14% of anthrax protective antigen (Koya et al.,
2005) and 16% of CTB-Pins in tobacco (Ruhlman et al.,
2007). In previous studies, expression of cholera vaccine
antigen has been demonstrated in edible crop plants
including carrot (Rosales-Mendoza et al., 2008), potato
(Arakawa et al., 1997) and tomato (Jani et al., 2002).
Recently CTB protein has been targeted to endoplasmic
reticulum in carrot but the expression level could reach up
to 0.48% of TSP (Kim et al., 2009). The expression level in
these nuclear transgenic crop plants ranged from 0.02%
to 0.48% of TSP. This low level of expression would
require large amount of plant material for human immuni-
zation. In the present study, the CTB-AMA1 and CTB-
MSP1, dual cholera-malaria vaccine antigens accumulated
100- to 600-fold higher in tobacco and 100- to 400-fold
higher in lettuce than nuclear expressed cholera vaccine
antigens. The cholera-malaria vaccine antigens expressed
in lettuce (6.1%–7.3% of TSP) is sufficient to perform ani-
mal and human clinical studies.
Production of a green vaccine for major infectious dis-
eases such as cholera and malaria with ease of administra-
tion that does not require cold chain is an important
need, especially in areas with limited access to cold stor-
age or transportation. Considering that mucosal surface is
the site for many gastrointestinal, respiratory and urogeni-
tal infections, developing an oral vaccine has great
significance. For instance gastrointestinal infections caused
by V. cholerae, Helicobacter pylori, Shigella spp. and ⁄or
by rotaviruses, Entamoeba histolytica are major examples
among many others. Many advantages of oral plant-
derived vaccines to confer immunity against aforemen-
tioned infectious agents were discussed previously (Daniell
et al., 2005; Holmgren and Czerkinsky, 2005; Davoodi-
Semiromi et al., 2009).
Our investigation is the longest cholera vaccine study
reported so far in the plant-derived vaccine literature. Ani-
mals were boosted until 267 days and were challenged on
day 303. Multiple oral boosters conferred durable immu-
nity, more than half of the mouse (BALB ⁄ c) life span. This
observation is important in the light of recent reports on
waning immunity against cholera (King et al., 2008). With
the current cholera vaccine, immunity is lost in children
within 3 years and adults are not fully protected (Olsson
and Parment, 2006). Although boosters beyond 5–8 times
did not significantly increase immunity levels, long-term
protection was maintained. No significant statistical differ-
ences were observed in CTB-IgA in sera of immunized mice
that received 5–8 injections when compared with antibody
level of the same mice with more than eight injections.
In the current study, we observed high level of CTB-IgA
only in ORV-CTB mice but not in SQV or AJV or ORV-UT
mice. In contrast, antigen presentation to the mucosal
immune system via a non-receptor-mediated delivery
resulted in little or no local antigen-specific IgA (Arlen
et al., 2008). Immunization by i.p. with outer membrane
vesicles of V. cholera failed to generate IgA (Schild et al.,
2008, 2009). These data suggest that induction of intesti-
nal IgA may require certain components of the gut
immune system, which does not exist in any other part of
the body. Further studies with antigens conjugated with
and without CTB or other proteins that bind to intestinal
receptors are necessary to understand the relationship
between antigen presentation and production of IgA.
Recently it has been shown that interaction of intestinal
IgA with other locally generated cytokines such as trans-
forming growth factor-b1, IL-10 and IL-4 will provide a
unique microenvironment to educate DC and subsequently
educated DC will imprint naı¨ve T cells (Alpan et al., 2004)
and imprinted T cells secrete the same cytokine profile as
previously antigen-experienced T cells. None of SQV mice
had detectable CTB-IgA; however, 89% of SQV mice were
protected from CT challenge. Our data show that only
serum CTB-IgG1 and not -IgG2a, -IgG2b, -IgG3 or -IgM
conferred immunity against CT challenge in SQV mice.
Our data also show that only CTB-IgM significantly
decreased after CT challenge, while other members of the
family remained the same.
In our study, CT induced up-regulation of IL-10 express-
ing CD4+ T cells, CTB-IgA and CTB-IgG1 in ORV and SQV,
ª 2009 The Authors
Journal compilation ª 2010 Blackwell Publishing Ltd, Plant Biotechnology Journal, 8, 223–242
Dual vaccine for cholera and malaria 235
respectively, suggesting that vaccination regimen elicited
Tr1 ⁄ Th2 immune response and protected vaccinated mice
against CT challenge. Up-regulation of IL-7Ra+Foxp3)CD4+
T cells in vaccinated mice after CT challenge is interesting
because it has been reported that formation of Peyer’s
patches is dependent upon IL-7 receptor, tumour necrosis
factor (TNF) and TNF super family members (Fu and Chap-
lin, 1999). Further experiments are needed to address
functional properties of IL-7R in plant-derived vaccines and
immunity. Furthermore, our data from single-cell-based
studies suggest that CT increased numbers of Foxp3+ reg-
ulatory T cells and co-stimulatory molecule CD80 in
splenocytes in unvaccinated control mice but CT had little
effect on this population in vaccinated mice. Increasing
numbers of Foxp3 regulatory T cells in unvaccinated mice
is interesting because this population is the most effective
arm of peripheral tolerance. Immediate consequences of
higher numbers of Foxp3+ regulatory T cell would be sup-
pression of responding T-cell populations to CT (Shevach,
2002). Because CT did not increase numbers of
CD4+CD25+high T cells (data not shown), it appears that
CT converts Foxp3)CD25)CD4+ T cells into Foxp3+ regula-
tory T cells in the periphery. In agreement with our data,
Sun et al. (2006) have reported increasing number of
Ag-specific Foxp3+ regulatory T cells by CTB and CTB+ CT
respectively. They have also demonstrated that intragaster-
ic administration of OVA-CTB-induced expression of anti-
gen-specific Foxp3+CD25+ regulatory T cells.
Despite the recent increase in knowledge of genomics
and proteomics of the malarial parasites, no licensed vac-
cine for the prevention of malarial disease is yet available
(Sharma and Pathak, 2008). The need for a malarial
vaccine is imperative because the global burden of the
disease is increasing due to drug resistance, mosquito’s
resistance to insecticides, ineffective control measures,
re-emergence of the disease and increased tourism. There
is a great need to create a low cost human malarial
vaccine with the elimination of laborious and expensive
purification techniques. Two leading blood-stage malarial
vaccine candidates, AMA1 and MSP1 were constructed in
a fusion cassette with CTB. It has been reported that
malarial antigens display poor immunogenicity even when
used with adjuvants (Sachdeva et al., 2006). Several strat-
egies for increasing immunogenicity of malarial antigens
include the use of different adjuvants, optimizing immuni-
zation protocols, using rabbits or monkeys for animal test-
ing, fusing malarial antigen with viral or bacterial
antigens, or constructing multivalent antigen chimeras
have been reported (Wang et al., 2003; Pan et al., 2004;
Qian et al., 2007; Greenwood et al., 2008). The expres-
sion of human malarial antigen, Plasmodium falciparum
MCP1 COOH-terminal region in tobacco plants via the
nuclear genome has been reported earlier (Ghosh et al.,
1993). Recently, the rodent malarial antigen, P. yoelii
codon-optimized MSP 4 ⁄5 was expressed in tobacco
transgenic plants (Wang et al., 2008) that showed modest
expression level (0.25% TSP). In our study, the human
malarial antigens consisting of domain III of AMA1 and
19-kDa C-terminal fragment of MSP1 showed high levels
of expression in both lettuce and tobacco chloroplasts (up
to 13.17% TSP). Expression of AT-rich P. falciparum
(Gardner et al., 2002) open-reading frames is compatible
with chloroplast expression system because the chloro-
plast genome is also AT-rich. The recombinant chimeric
antigen was found to be highly immunogenic in mice.
Our in vitro inhibition assay provided evidence that the
antibodies generated from immunized mice were effective
in preventing parasite invasion of RBC. Evaluation of
human vaccine antigens (P. falciparum) in the rodent
model system has major difficulties. Malaria challenge
failed when mice are vaccinated with P. falciparum and
challenged with P. berghei (de Koning-Ward et al., 2003).
One solution to this problem is to challenge immunized
mice with the P. berghei ⁄ P. falciparum (Pb-PfM19) chime-
ric line that expresses the P. falciparum MSP1 (Thomas
et al., 1994). Parasite challenge was shown to be success-
ful to protect mice when animals were passively immu-
nized with anti-PfMSP142 antibody and then challenged
with chimeric line (Sachdeva et al., 2006). However, in
our study this chimeric P. berghei line was ineffective
because administration of this strain did not cause malaria
in unimmunized control mice.
In conclusion, this study for the first time demonstrates
possibility of generation of multivalent green vaccine
against two major infectious diseases, cholera and malaria.
Currently, other than the rotavirus, there is no other
example of oral vaccines in the US and the mucosal
immune system has not been utilized to confer immunity
against invading pathogens. Oral polio vaccine was discon-
tinued in the US because one in 2.4 million cases con-
tracted polio from the live attenuated oral vaccine.
However, such problems are not associated with subunit
vaccines because only one or two antigens are used that
are incapable of causing any disease. Therefore, it is
important to understand and utilize the mucosal immune
system for delivery of subunit vaccines. Bioencapsulation
of vaccine antigens in plant cells provide an ideal low cost
delivery system for large-scale distribution at times of
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crisis. In addition, oral delivery confers dual protection via
systemic and mucosal immune system. High level and
long-term protection observed against cholera toxin chal-
lenge and against the malarial parasite in mice sera immu-
nized with chloroplast-derived antigens, makes this system
yet another new platform for advancing towards human
clinical studies.
Experimental procedures
Chloroplast vector construction and regeneration of
transplastomic plants
The AMA1 and MSP1 were synthesized (Pan et al., 2004) and
cloned into the pGEMT Easy Vector (Promega, Madison, WI,
USA). The CTB sequence was amplified using pLD-5¢-UTR-CTB-
Pins (Ruhlman et al., 2007) vector as the template. Further, the
sequences were verified to check any errors, fused and subcloned
into the pBSSK+ (Stratagene, La Jolla, CA, USA) vector. CTB-
AMA1 fusion had GPGP hinge region and the furin cleavage site
while CTB-MSP1 only had the GPGP hinge in between fusion pro-
teins to facilitate correct folding of each protein by reducing the
steric hindrance. The CTB-AMA1 and CTB-MSP1 expression cas-
sette was created with tobacco regulatory elements and ligated
into the pLDctv tobacco chloroplast transformation vector to
obtain pLD CTB-AMA1 and pLD CTB MSP1 (Daniell et al., 1998,
2004). Leaves of Nicotiana tabacum var. Petite Havana were bom-
barded with pLD CTB-AMA1 and pLD CTB-MSP1 and the trans-
formants were obtained as described earlier (Singh et al., 2009).
The pUC-based Lactuca sativa long flanking plasmid sequence
(pLSLF) was used to integrate foreign genes into the intergenic
spacer region between the trnI (Ile) and trnA (Ala) genes as
described previously (Ruhlman et al., 2007; Verma et al., 2008).
The Prrn: aadA: rbcL selectable marker gene cassette was assem-
bled in pBSSK+ vector and contained the rrn promoter and rbcL
3¢-UTR amplified from the lettuce chloroplast genome. The aadA
expression cassette was subcloned into pLSLF resulting in the
pLsDV vector. The pLsDV CTB-AMA1 and pLsDV CTB-MSP1 were
constructed using CTB-AMA1 and CTB-MSP1 expression cassette
with the psbA promoter, 5¢- and 3¢-UTR from lettuce. All cloning
steps to create chloroplast transformation vectors were performed
in Escherichia coli using standard molecular biology protocols
(Sambrook and Russell, 2001; Verma et al., 2008). Lactuca sativa
var. Simpson elite was transformed and the transplastomic lines
were selected as described previously (Ruhlman et al., 2007). PCR
reactions were performed using two sets of primers namely
3P ⁄ 3M or 16SF ⁄ 3M and 5P ⁄ 2M. Southern blot analysis was per-
formed to confirm transgene integration as well as homoplasmy
as described earlier (Singh et al., 2009).
Immunoblot analysis and enrichment of chloroplast-
derived proteins
Chloroplast-derived CTB-malarial proteins were extracted from
100 mg of powdered leaf material. Plant extraction buffer
[200 lL; 100 mM NaCl, 10 mM ethylenediaminetetraacetic acid
(EDTA), 200 mM Tris–HCl pH8, 0.05% Tween 20, 0.1% sodium
dodecylsulphate (SDS), 14 mM b-mercaptoethanol, 200 mM dith-
iothreitol, 200 mM sucrose, Roche complete mini EDTA-free prote-
ase inhibitor cocktail] was added to the ground leaf material.
Ground samples were placed on ice and mixed for 2 min using a
mechanical pestle and centrifuged at 700 g for 15 min at 4 C to
obtain the supernatant (soluble fraction). The pellet (insoluble
fraction) was resuspended with equal volume of the protein
extraction buffer and sonicated for 30 s. The supernatant and pel-
let were subjected to Bradford analysis to determine the total pro-
tein concentration.
After estimation of TSP using Bradford method, 2 ⁄ 3 lg of TSP
from sample was separated in 12% SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to nitrocellulose mem-
branes for immunoblotting as described earlier (Verma et al.,
2008). The protein separated by SDS-PAGE gel was transferred to
nitrocellulose membrane by electroblotting and the membrane
was blocked overnight with 3% non-fat dry milk. To detect CTB-
AMA1 and CTB-MSP1-fused proteins, blots were incubated with
1 : 3000 rabbit anti-CTB primary polyclonal antibody (Sigma, St
Louis, MO, USA) followed by 1 : 5000 HRP-conjugated donkey
anti-rabbit secondary antibody (Southernbiotech, Birmingham, AL,
USA). A SuperSignal West Pico chemiluminescence substrate Kit
(Pierce, Rockford, IL, USA) was used for autoradiographic
detection.
For enrichment, chloroplast-derived CTB-malarial proteins were
extracted from 10 g freeze-dried leaf materials. The samples were
placed on ice and homogenized for 5 min with an OMNI Inter-
national (Kennesaw, GA, USA) (GLH-2596) probe and centrifuged
at 700 g for 15 min at 4 C. The supernatant was collected and
then subjected to TALON superflow Metal Affinity Resin (Clon-
tech) to enrich the chloroplast-derived CTB-malarial proteins
according to manufacturer’s instructions. The eluted fraction was
collected and subjected to the Bradford Protein assay (BioRad)
and to the RC-DC Protein Assay (Bio-Rad, Hercules, CA, USA).
The eluted fractions were dialysed with sterile phosphate-buffered
saline (PBS) and the Slide-A-Lyzer Dialysis Cassette 10 000 MW
(Pierce).
Cholera toxin-B-GM1-ganglioside receptor binding
assay
A 96 well microtiter plate was coated with GM1-ganglioside recep-
tor (Sigma G-7641) by incubating 100 lL GM1 (3 lg ⁄mL) in bicar-
bonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) at 4 C
overnight. The wells were blocked with 200 lL of 3% fat-free milk
in PBST (PBS with 0.05% Tween-20) for 2 h followed by three
washes with PBST and water. The plate was incubated with various
concentrations of TSP from leaves of transformed and
untransformed plants in bicarbonate buffer (100 lL per well) over-
night at 4 C. The plate was washed three times with PBST and
water, the wells were blocked with 200 lL per well of 3% fat-free
milk in PBST at 37 C for 2 h followed by three washes with PBST
and water. The plate was incubated with 1 : 4000 dilution of rabbit
anti-CTB antibody for 2 h followed by three washes with PBST and
water, followed by incubation for 2 h with 1 : 4000 dilution of
goat-anti-rabbit IgG, conjugated to horseradish peroxidase. Colour
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was developed using tetra methyl benzidine (TMB) as substrate.
Reaction was stopped by adding 50 lL of 2 N H2SO4 and the absor-
bance was read on a plate reader (BioRad) at 450 nm.
Enzyme-linked-immunosorbent serologic assay
Sandwich ⁄ antigen-specific ELISA was performed as described ear-
lier (Arlen et al., 2008). In malaria studies, we used sera from
bleed number 4 and 5 at dilution cited in the text, however, in
cholera studies sera from terminal bleeding was used except sta-
ted otherwise at dilution mentioned in the text.
Mice and immunization schedule
Enriched chloroplast-derived proteins (2.5 mg) from transgenic
tobacco crude extract was mixed with 1 : 4 diluted Alhydrogel
(Aluminium Hydroxide Gel; Sigma) in PBS and incubated overnight
with gentle rocking at 4 C. The samples were centrifuged at
2000 g for 5 min at 4 C. The RC-DC Protein Assay (BioRad) was
used to determine the adsorption efficiency by comparing the
total amount of protein added with the adjuvant and the protein
remaining in the supernatant after binding to adjuvant. The pro-
tein-adsorbed pellet was resuspended in sterile PBS to a final con-
centration of 1 lg ⁄ lL. For subcutaneous injections, 100 lL of
Alhydrogel or chloroplast-derived protein (25 lg) adsorbed to
Alhydrogel was injected into the scruff of the neck using a tuber-
culin syringe fitted with a 27-G needle. The leaf material for oral
delivery was ground in liquid nitrogen with mortars and pestles
and stored at )80 C until the day of immunization. Oral doses
(500 mg each) of either untransformed or transgenic leaf material
was resuspended in 200 lL of sterile PBS and homogenized on ice
for 5 min with an OMNI International (GLH-2596) probe. The plant
cell suspension was stored on ice until oral delivery. The plant cell
suspension (200 lL) was delivered via oral gavage by using a
tuberculin syringe and a 20-G bulb-tipped gastric gavage needle.
Ninety female BALB ⁄ c mice, purchased from the Charles River
Laboratories (Wilmington, MA, USA) at 7 week of age, were
housed at the University of Central Florida mouse facility in venti-
lated cages under specific pathogen-free conditions. All mice and
procedures performed in this study are based on an approved
protocol and are in accordance with the UCF-IACUC. Mice were
randomly divided into nine groups (n = 10 per group): group 1:
oral UT group gavaged with untransformed leaves; group 2: adju-
vant with no bound antigen; group 3: CTB-AMA1 purified anti-
gen with adjuvant; group 4: oral gavage with leaves expressing
CTB-AMA1; group 5: CTB-MSP1 purified antigen with adjuvant;
group 6: oral gavage with leaves expressing CTB-MSP1; group 7,
CTB-MSP1 and CTB-AMA1 purified antigens bound with adjuvant;
group 8: oral gavage with leaves expressing CTB-AMA1 and
MSP1 and group 9: untreated mice. Mice in groups 2–8 were ini-
tially primed subcutaneously with corresponding antigen followed
by oral and ⁄ or subcutaneous boosts in the course of this study.
Mice in subcutaneous group received boosts on days 13, 27, 43,
55, 155 and 219. Mice in oral gavage group received boosts on
days 10, 17, 24, 31, 37, 45, 52, 59, 150, 157, 189 and 219. Final
oral and subcutaneous boosts were given on day 219 and mice
were challenged with CT toxin 2 weeks after the final boost.
Cholera toxin challenge and intestinal water content
Cholera toxin (CT) (C8052; Sigma) was diluted (final concentra-
tion 1 mg ⁄mL) in PBS buffer containing 6% NaHCO3 and 0.5%
albumin. Effective dose of CT was determined empirically and
unvaccinated BALB ⁄ c mice with the same age and sex as of our
experimental group were given different doses of CT (1, 1.5, 2, 3
and 4 lg ⁄ g of body weight) for 14 h. Based on these data, mice
were challenged with a CT dose of 1.5 lg ⁄ g of body weight. The
mice remained in their cages without food but water ad libitum.
The mice were scarified after 14 h and intestinal water retention
was collected and measured.
Measurement of immunoglobulin and cytokines
All sera used in this study for cytokines and antibodies detection
was from terminal bleeding except stated otherwise. Sandwich
ELISA was performed on mice sera for cytokines detection (Arlen
et al., 2008). Sandwich ELISA for different cytokines was per-
formed as described (Arlen et al., 2008). Plates (96-well) were
coated with anti-mouse IL-2 (2 lg ⁄mL), IL-4 (2 lg ⁄mL), IFNc
(2 lg ⁄mL), IL-17A (2 lg ⁄mL) antibodies (all from eBiosciences, San
Diego, CA, USA) using carbonate buffer (pH = 9.6) at 4 C for
12–16 h. Plates were washed and hybridized with diluted sera at
37 C for 1 h. Detection was performed as described earlier. Cap-
ture ELISA for CTB-antigen-specific IgA, IgG1, IgG2a, IgG2b, IgG3,
IgM antibodies in sera and intestinal content (IgA only) of different
group of mice were performed by coating 96-well flat bottom
plate with 1 lg ⁄mL (100 lL) of CTB (Sigma) in carbonate buffer
(pH = 9.7) at 4 C for 12–16 h. All rat anti-mouse IgG1 antibodies
were purchased from Southern Biotech, AL.HRP-conjugated strep-
tavidin (1 : 4000; Peirce) and TMB were used for detection and
substrate respectively. For CTB-antigen-specific IgA in sera and
intestinal content, goat-anti-mouse IgA-HRP (1 : 2000l; American
Qualex) was used. Rabbit anti-CTB Ab (1 : 4000; Sigma) and anti-
rabbit IgG-HRP Ab (1 : 7500) were used as primary and secondary
antibodies for CTB respectively.
Flow cytometry analysis
Flow cytometry analysis was performed on fresh single-cell sus-
pension of splenocytes. Cell surface staining on freshly prepared
splenocytes was performed using anti-mouse CD4 (L3T4; BD
Pharmingen, San Diego, CA, USA), CD25 (3C7; BD Pharmingen),
CD127 (IL-7Ra) (SB ⁄ 199; BD Pharmingen), CD44 (IM7; BD Pharm-
ingen), CD11c (HL3; BD Pharmingen), CD80 (16-10A1; eBio-
science), biotin-conjugated MHC II (M5 ⁄ 114.15.2; eBioscience).
Purified rat anti-mouse CD16 ⁄CD32 (2.4G2; BD Pharmingen) was
used to block Fc receptor in myeloid cell lineages.
Intra-cellular staining of Foxp3 (FJK, 16S; eBioscience), IL-4
(11B11; eBiosciences), IL-10 (JES5-16E3; eBioscience), IFNc
(XMG1.2; eBioscience) was performed using foxp3 intra-cellular
staining kit (eBioscience) according to instructions provided by man-
ufacturer. Flow cytometry was performed using FACSCalibur (BD
Bioscience, San Jose, CA, USA) and 30 000 events were acquired
for each condition and data analysis was performed using FCS
express (v3) software (De Novo soft ware, Los Angeles, CA, USA).
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Immunofluorescence detection of malarial antigens
with sera of vaccinated mice
A revised protocol was adopted for the preparation and fixation
of RBC (Tonkin et al., 2004) and for detection of antigen with
immunofluorescence (Ayong et al., 2007). Diluted sera (1 : 500)
were hybridized on RBC followed by hybridization with diluted
(1 : 1000) Alexa Fluor 555 goat-anti-mouse antibody. Cells were
allowed to settle on previously coated coverslips with 1% PEI for
30 min at room temperature. The mounting solution, 50% glyc-
erol with 0.1 mg ⁄mL of DABCO (Sigma) was added to cover slips
and then inverted on microscope slides. Fluorescence images were
observed and captured by the LSM 510 confocal laser scanning
microscope (Carl Zeiss, Jena Germany).
In vitro parasite inhibition assay
The 3D7 P. falciparum culture was synchronized with ring stage
parasites with sorbitol lysis. The parasite completed one cycle and
was allowed to mature to the trophozoite-schizont stage. The
haematocrit and parasitemia were adjusted to 2% (2.5% parasitemia
for the MRA-35 PfMSP119 in vitro parasite inhibition assay). Mouse
sera (bleed 4) and MRA-35 PfMSP119 (positive control) were heat
inactivated at 56 C for 30 min and hybridized on human RBC over-
night at 4 C (Sachdeva et al., 2006). The mouse serum was added
to the parasite culture in 96-well plates at a final concentration of
20% (for the MRA-35 PfMSP119 in vitro parasite inhibition assay 5 lL
of antibody was added and diluted 1 : 5–1 : 625 to 25 lL of parasite
culture). To serve as a negative control, no serum was added to wells
and replaced with culture media. The cultures were incubated for
48 h to allow for schizont rupture and merozoite invasion. The assays
were preformed in duplicate and repeated at least three times.
For microscopic analysis using the 100· oil immersion lens,
blood smears were made and stained with Giemsa and the num-
bers of parasites per 900–1100 RBC were determined for each
well. Parasitemia was measured using the following formula
(infected RBC ⁄ infected + uninfected RBC) · 100. Per cent of inhi-
bition was determined by the following formula (% parasitemia
of no sera added ) % parasitemia of experimental mouse sera ⁄%
parasitemia of no sera added) · 100. Relative per cent of inhibi-
tion was determined by the following formula [% of inhibition
from experimental mouse sera ⁄% inhibition of MRA-35 PfMSP119
(positive control)] · 100 and the per cent of inhibition for the
positive control was set at 100%.
Statistical analysis
Data are reported as the mean ± SD. All analyses for statistically
significant differences were performed using one-way ANOVA and the
t-test (GRAPHPAD PRISM 5, GraphPad Software, La Jolla, CA, USA) and P
values <0.05 were considered significant.
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